Protein kinase C isozymes and their selectivity towards ruboxistaurin

Proteins: Structure, Function and Genetics

Volumn 72, Issue 1, 2008, Pages 447-460

  Tang, Sishi ^a,b   Xiao, Victor ^a,b   Wei, Lianhu ^a   Whiteside, Catharine I ^a,c   Kotra, Lakshmi P ^a,b,d,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^e MaRS Centre   (Canada)

Author keywords

Binding affinity; Docking; Protein kinase C; Ruboxistaurin; Selectivity

Indexed keywords

ISOENZYME; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C ZETA; RUBOXISTAURIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CATALYSIS; CORRELATION ANALYSIS; DRUG BINDING; DRUG DESIGN; DRUG SELECTIVITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; IC 50; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; THREE DIMENSIONAL IMAGING;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; BINDING SITES; HYDROGEN BONDING; INDOLES; ISOENZYMES; MALEIMIDES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN KINASE C; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; STRUCTURAL HOMOLOGY, PROTEIN; SUBSTRATE SPECIFICITY; THERMODYNAMICS;

EID: 44949141565     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21942     Document Type: Article

References (63)

1. Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chem 1995;270:28495-28498.
2. Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001;101:2353-2364.
3. Alvi F, Idkowiak-Baldys J, Baldys A, Raymond JR, Hannun YA. Regulation of membrane trafficking and endocytosis by protein kinase C: emerging role of the pericentrion, a novel protein kinase C-dependent subset of recycling endosomes. Cell Mol Life Sci 2007;64:263-270.
4. Carpenter L, Cordery D, Biden TJ. Protein kinase Cdelta activation by interleukin-1beta stabilizes inducible nitric-oxide synthase mRNA in pancreatic beta-cells. J Biol Chem 2001;276:5368-5374.
5. Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1997;76:21-31.
6. Takahashi T, Kojima Y, Tsunoda Y, Beyer LA, Kamijo M, Sima AA, Owyang C. Impaired intracellular signal transduction in gastric smooth muscle of diabetic BB/W rats. Am J Physiol 1996;270:G411-G417.
7. Whiteside CI, Dlugosz JA. Mesangial cell protein kinase C isozyme activation in the diabetic milieu. Am J Physiol Renal Physiol 2002;282:F975-F980.
8. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-866.
9. Ohno S, Akita Y, Hata A, Osada S, Kubo K, Konno Y, Akimoto K, Mizuno K, Saido T, Kuroki T, Suzuki K. Structural and functional diversities of a family of signal transducing protein kinases, protein kinase C family, two distinct classes of PKC, conventional cPKC and novel nPKC. Adv Enzyme Regul 1991;31:287-303.
10. Jaken S. Protein kinase C isozymes and substrates. Curr Opin Cell Biol 1996;8:168-173.
11. Shen GX. Selective protein kinase C inhibitors and their applications. Curr Drug Targets Cardiovasc Haemoatol Disord 2003;3:301-307.
12. Joy SV, Scates AC, Bearelly S, Dar M, Taulien CA, Goebel JA, Cooney MJ. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. Ann Pharmacother 2005;39:1693-1699.
13. Konishi H, Tanaka M, Takemura Y, Matsuzaki H, Ono Y, Kikkawa U, Nishizuka Y. Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc Natl Acad Sci USA 1997;94:11233-11237.
14. Chou MM, Hou W, Johnson J, Graham LK, Lee MH, Chen CS, Newton AC, Schaffhausen BS, Toker A. Regulation of protein kinase C zeta by PI 3-kinase and PDK-1. Curr Biol 1998;8:1069-1077.
15. Behn-Krappa A, Newton AC. The hydrophobic phosphorylation motif of conventional protein kinase C is regulated by autophosphorylation. Curr Biol 1999;9:728-737.
16. Newton AC. Regulation of protein kinase C. Curr Opin Cell Biol 1997;9:161-167.
17. Mochly-Rosen D, Gordon AS. Anchoring proteins for protein kinase C: a means for isozyme selectivity. FASEB J 1998;12:35-42.
18. Bell RM, Burns DJ. Lipid activation of protein kinase C. J Biol Chem 1991;266:4661-4664.
19. Newton AC. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J 2003;370:361-371.
20. Ohno S, Konno Y, Akita Y, Yano A, Suzuki K. A point mutation at the putative ATP-binding site of protein kinase C alpha abolishes the kinase activity and renders it down-regulation-insensitive. A molecular link between autophosphorylation and down-regulation. J Biol Chem 1990;265:6296-6300.
21. Ward NE, O'Brian CA. The intrinsic ATPase activity of protein kinase C is catalyzed at the active site of the enzyme. Biochemistry 1992;31:5905-5911.
22. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
23. O'Brian CA, Ward NE. Staurosporine: a prototype of a novel class of inhibitors of tumor cell invasion? J Natl Cancer Inst 1990;82:1734-1735.
24. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH, III, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M, Ballas LM, Hall SE, Winneroski LL, Faul MM. (S)-13-[(dimethylamino)methyl]-10,11,14,15- tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem 1996;39:2664-2671.
25. Wheeler GD. Ruboxistaurin (Eli Lilly). Inv Drugs 2003;6:59-63.
26. Burkey JL, Campanale KM, O'bannon DD, Cramer JW, Farid NA. Disposition of LY333351, a selective protein kinase C β inhibitor, in Fischer 344 rat and beagle dog. Xenobiotica 2002;32:1045-1052.
27. Goekjian PG, Jirousek MR. Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in the development. Curr Med Chem 1999;6:877-903.
28. Frank RN. Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol 2002;133:693-698.
29. Miller BW, Baier LD, Morrison AR. Overexpression of protein kinase C-zeta isoform increases cyclooxygenase-2 and inducible nitric oxide synthase. Am J Physiol 1997;273:C130-C136.
30. Ritch P, Rudin CM, Bitran JD, Edelman MJ, Makalinao A, Irwin D, Lilenbaum R, Peterson P, John WJ. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced nonsmall cell lung cancer. Lung Cancer 2006;52:173-180.
31. Messerschmidt A, Macieira S, Velarde M, Badeker M, Benda C, Jestel A, Brandstetter H, Neuefeind T, Blaesse M. Crystal structure of the catalytic domain of human atypical protein kinase C-iota reveals interaction mode of phosphorylation site in turn motif. J Mol Biol 2005;352:918-931.
32. Xu ZB, Chaudhary D, Olland S, Wolfrom S, Czerwinski R, Malakian K, Lin L, Stahl ML, Joseph-McCarthy D, Benander C, Fitz L, Greco R, Somers WS, Mosyak L. Catalytic domain crystal structure of protein kinase C-theta (PKCtheta). J Biol Chem 2004;279:50401-50409.
33. Komander D, Kular GS, Schuttelkopf AW, Deak M, Prakash KR, Bain J, Elliott M, Garrido-Franco M, Kozikowski AP, Alessi DR, van Aalten DM. Interactions of LY333531 and other bisindolyl maleimide inhibitors with PDK1. Structure 2004;12:215-226.
34. Beveridge DL, DiCapua FM. Free energy via molecular simulation: applications to chemical and biomolecular systems. Annu Rev Biophys Biophys Chem 1989;18:431-492.
35. Case DA, Caldwell JW, Cheatham TE, III, Wang J, Ross WS, Simmerling CL, Darden TA, Merz KM, Stanton RV, Cheng AL, Vincent JJ, Crowley M, Tsui V, Gohlke H, Radmer RJ, Duan Y, Pitera J, Massova I, Seibel GL, Singh UC, Weiner PK, Kollman PA. AMBER 7, University of California, San Francisco, 2002.
36. Soliva R, Almansa C, Kalko SG, Luque FJ, Orozco M. Theoretical studies on the inhibition mechanism of cyclooxygenase-2. Is there a unique recognition site? J Med Chem 2003;46:1372-1382.
37. Camps P, Gomez E, Munoz-Torrero D, Badia A, Vivas NM, Barril X, Orozco M, Luque FJ. Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors. J Med Chem 2001;44:4733-4736.
38. Steinbrecher T, Case DA, Labahn A. A multistep approach to structure-based drug design: studying ligand binding at the human neutrophil elastase. J Med Chem 2006;49:1837-1844.
39. Cole C, Reigan P, Gbaj A, Edwards PN, Douglas KT, Stratford IJ, Freeman S, Jaffar M. Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. J Med Chem 2003;46:207-209.
40. Bairoch A, Apweiler R, Wu CH, Barker WC, Boeckmann B, Ferro S, Gasteiger E, Huang H, Lopez R, Magrane M, Martin MJ, Natale DA, O'Donovan C, Redaschi N, Yeh LS. The universal protein resource (UniProt). Nucleic Acids Res 2005;33:D154-D159.
41. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-410.
42. Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003;31:3381-3385.
43. Chothia C, Lesk AM. EMBO J 1986;5:823-826.
44. Swissmodel: Reliability of models. Available at http://swissmodel.expasy. org//SM_LikelyPrecision.html.
45. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998;19:1639-1662.
46. Frisch MJTGW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Montgomery JA, Jr, Vreven T, Kudin KN, Burant JC, Millam JM, Iyengar SS, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson GA, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Klene M, Li X, Knox JE, Hratchian HP, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Ayala PY, Morokuma K, Voth GA, Salvador P, Dannenberg JJ, Zakrzewski VG, Dapprich S, Daniels AD, Strain MC, Farkas O, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Ortiz JV, Cui Q, Baboul AG, Clifford S, Cioslowski J, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Gonzalez C, Pople JA. Gaussian 98. Wallingford, CT: Gaussian; 1998.
47. Kollman P. Free energy calculations: applications to chemical and biochemical phenomena. Chem Rev 1993;93:2395-2417.
48. Gohlke H, Case DA. Converging free energy estimates: MM-PB(GB)SA studies on the protein-protein complex Ras-Raf. J Comput Chem 2004;25:238-250.
49. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE, III. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000;33:889-897.
50. Sharp KA, Honig B. Electrostatic interactions in macromolecules: theory and applications. Annu Rev Biophys Biophys Chem 1990;19:301-332.
51. Sitkoff D, Sharp KA, Honig B. Accurate calculation of hydration free energies using macroscopic solvent models. J Phys Chem 1994;98:1978-1988.
52. Schutz CN, Warshel A. What are the dielectric "constants" of proteins and how to validate electrostatic models? Proteins 2001;44:400-417.
53. Green DF, Tidor B. Design of improved protein inhibitors of HIV-1 cell entry: optimization of electrostatic interactions at the binding interface. Proteins 2005;60:644-657.
54. Sharp K, Jean-Charles A, Honig B. Local dielectric constant model for solvation free energies which accounts for solute polarizability. J Phys Chem 1992;96:3822-3828.
55. Hawkins GD, Cramer CJ, Truhlar DG. Parametrized models of aqueous free energies of solvation based on pairwise descreening of solute atomic charges from a dielectric medium. J Phys Chem 1996;100:19824-19839.
56. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996;261:470-489.
57. Fischer S, Smith JC, Verma SC. Dissecting the vibrational entropy change on protein/ligand binding: burial of a water molecule in bovine pancreatic trypsin inhibitor. J Phys Chem 2001;105:8050-8055.
58. Donini OA, Kollman PA. Calculation and prediction of binding free energies for the matrix metalloproteinases. J Med Chem 2000;43:4180-4188.
59. Wang J, Morin P, Wang W, Kollman PA. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc 2001;123:5221-5230.
60. Massova I, Kollman PA. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect Drug Discov Design 2000;18:113-135.
61. Engel GL, Farid NA, Faul MM, Richardson LA, Winneroski LL. Salt form selection and characterization of LY333531 mesylate monohydrate. Int J Pharm 2000;198:239-247.
62. Hendsch ZS, Tidor B. Electrostatic interactions in the GCN4 leucine zipper: substantial contributions arise from intramolecular interactions enhanced on binding. Protein Sci 1999;8:1381-1392.
63. Kentsis A, Sosnick TR. Trifluoroethanol promotes helix formation by destabilizing backbone exposure: desolvation rather than native hydrogen bonding defines the kinetic pathway of dimeric coiled coil folding. Biochemistry 1998;37:14613-14622.